INSPIRATION HEALTHCARE GROUP

WALBROOK INVESTOR RELATIONS

Inspiration Healthcare Group plc (AIM: IHC)

Company Summary

November 2026

Investment Profile

1. World class expertise and portfolio of best-in-class, innovative products
2. Addressing a critical need in a large and growing market
3. Long-term relationships with customers and partners
4. Well positioned for future growth, with an established commercial footprint and focused commercial strategy
5. Highly experienced leadership team with a proven commercial track record
6. History of delivering organic growth and M&A

Share Information

Ticker	IHC
Share Price	17.50p
Shares in issue	89.66m
Market Cap	£15.69m
12m Hi/Low	32.00p/12.30p

(Source: The London Stock Exchange, November 2026)

12-Month Share Price



(Source: The London Stock Exchange, November 2026)

Major Shareholders (as of October 2026)

Name	%
Charter Kontron Limited Ltd	25.03
BGF Investments	21.04
Mr Simon Motley	4.71
Liontrust Asset Mgt	4.62
Interactive Investor	4.06
Mr Toby Foster	3.82
Stonehage Fleming	3.82
A J Bell Securities	3.65
Castlefield Investments	3.54
Hargreaves Lansdown Asset Mgt	3.18

Company Overview

Inspiration Healthcare Group plc (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

Distribution in 75+ Countries

British Based Manufacturing

~175 Employees

Three Business Units in Three Distinct Markets

Inspiration Healthcare Group encompasses three brands and operates in three market segments.

SLE

Global innovation leader in neonatal ventilation with a portfolio of neonatal ventilators, consumables and accessories

Inspiration Healthcare

UK/Ireland medtech distributor focusing on SLE vents, and other 3rd party neonatal products

Airon

Global champion of pneumatic ventilation, providing pneumatic ventilators, consumables and accessories

Each of the business units offer different potential in terms of size, while achieving faster-than-market growth rates. SLE has the largest opportunity with a **total neonatal addressable market of ~$430m**, and the Company is targeting to double revenue for each segment by 2030.

WALBROOK INVESTOR RELATIONS
For more information email: InspirationHealthcare@walbrookpr.com
Tel: 020 7933 8780; web: www.walbrookpr.com

Neonatal Intensive Care: Large and Growing Market


IHC is addressing a critical need within the global neonatal ICU market, which is valued at $7.7bn and expected to grow c.6.46% over the next five years. Every year 15 million babies are born prematurely and this number is rising - it is the single biggest cause of death of children under the age of five. Global growth drivers in the market include:

- Increase in healthcare infrastructure
- Increase in premature births
- Technology advancements
- Increase in Affordability



SLE offers the largest market opportunity for IHC (~$430m TAM) and is already established as the global innovation leader in neonatal ventilation and market leader in the UK. SLE is positioned to become the long term total solution in the market, aiming to capture 10-20% of US market share in 3-5 years with expected revenue of $10-20m combined for devices, consumables and service.

SLE is already showing strong growth, with underlying revenue in H1 27 increasing 35% to £13.4m, including 32% growth in UK/Ireland and 37% growth internationally. The Company's strategic focus remains on US market access for SLE's neonatal ventilator, with the development project on track for completion in H2 FY28.



Strong foundations for growth

The strong underlying growth demonstrated in H1 27 shows the strength of core SLE business without the benefit of one-off large orders. The current orderbook and opportunity pipeline provide confidence in upgraded FY27 revenues of at least £43m. Furthermore, the Company's short and mid-term product roadmap is on track, focusing on:

- Product enhancements
- Own consumables launches
- Strengthen service business
- US market access
- Continuing search for additional neonatal products to broaden the Company's portfolio

Experienced Management Team



Raffi Stepanian, CEO, joined IHC in January 2025, bringing over 20 years of senior leadership experience in international medical device companies. He has expertise in respiratory, anaesthesia, and monitoring, with a strong track record in the ventilator market. Previously, he was CEO of Breas Medical, where he led a successful transformation and launched new products in Europe and the US. Before that, he held a leadership role at GE Healthcare, shaping growth strategy and marketing for anaesthesia and ventilation.



Alan Olby, CFO, is a Chartered Accountant and experienced and commercially focused healthcare CFO. He spent 16 years at Sinclair Pharma, of which 12 years were as CFO and he was instrumental in transforming the company into a fast growth global aesthetics business, which was sold to Huadong Medicine Co Ltd for £165 million in 2018.

H1 FY27 Results

- Group revenue £22.0m (H1 FY26: £24.0m), with strong underlying growth ahead of market expectations (prior year benefitted from £6.5m one-off export orders)
- SLE revenue +35% to £13.4m, Inspiration Healthcare +9% to £7.0m, and Airon +40% to £1.6m
- Gross profit of £9.2m (H1 FY26: £11.1m)
- Adjusted EBITDA of £1.2m (H1 FY26: £1.3m)
- SLE outperforming both in UK & Ireland and International
- Consumables projects on track for launches in Q4 FY27
- Transition of Infusion therapies distribution to Micrel underway – with sales performance on plan

Post Period

- FY27 revenue expectation upgraded to at least £43m, positive momentum expected to continue into FY28
- Credit approval received for renewal of RCF facility for a new 3-year term with option to extend

Meet Inspiration Healthcare Group

View the latest Company presentation and register for future presentations by signing up to **Investor Meet Company** here.

Analyst Consensus as of November 2026 (Source: Factset)

	Jan '25	Jan '26	Jan '27 (Est.)	Jan '28 (Est.)	Jan '29 (Est.)
Sales (£m)	38.3	47.5	43.1	35.1	38.2
Adj. EBITDA (£m)	0.2	2.8	1.9	1.2	2.3
PBT (£m)	(2.2)	0.2	(0.5)	(1.2)	(0.4)